NDAOPHTHALMICSOLUTION/DROPS
Approved
Jun 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
5/8 — Partial
ISTALOL (timolol maleate) by Bausch + Lomb is 1 and beta 2 (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. First approved in 2004.
Drug data last refreshed 18h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ISTALOL is a topical ophthalmic solution containing timolol maleate, a non-selective beta-adrenergic receptor antagonist. It reduces elevated intraocular pressure in patients with glaucoma or ocular hypertension by primarily decreasing aqueous humor formation. The drug is applied as eye drops and maintains IOP-lowering effects for up to 24 hours with a single dose.
$0.803MPart D
LOE ApproachingProduct is in late-stage lifecycle with modest Part D utilization (~1,574 claims in 2023), signaling a mature, stable franchise with limited growth opportunities.
Mechanism of Action
1 and beta 2 (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients…
Indications
Worked on ISTALOL at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.